Oncogenic Role of GLMN in Liver Hepatocellular Carcinoma

Abstract

Liver cancer, particularly liver hepatocellular carcinoma (LIHC), is one of the most lethal malignancies worldwide with increasing incidence rates. This study investigated the role of the GLMN (Glomulin) gene in the progression of liver cancer and its potential as a diagnostic biomarker and therapeutic target. Using data from TCGA, GEPIA, and CPTAC databases, we analysed and compared GLMN expression levels between liver cancer tissues and normal tissues and explored the correlation between GLMN expression and patient survival outcomes. Our results showed that GLMN was significantly overexpressed in LIHC, and higher expression was associated with poor overall survival and disease-free survival. Additionally, we found a positive correlation between GLMN expression and CD8+ T cell infiltration, suggesting its involvement in the regulation of the tumour immune microenvironment. Gene enrichment analysis revealed that GLMN is involved in ubiquitin-mediated proteolysis and cell cycle regulation, highlighting its role in cancer progression. These findings suggest that GLMN may serve as a prognostic marker and therapeutic target for liver cancer.